Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden.
作者信息
Meltzer Herbert Y
机构信息
Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37212, USA.
出版信息
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3019-20. doi: 10.1073/pnas.0700090104. Epub 2007 Feb 20.
Abstract
摘要
相似文献
1
Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden.阐明某些抗精神病药物引起代谢负担的分子基础。
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3019-20. doi: 10.1073/pnas.0700090104. Epub 2007 Feb 20.
2
Antipsychotic drugs and schizophrenia.抗精神病药物与精神分裂症
N Engl J Med. 2006 Jan 19;354(3):298-300; author reply 298-300.
3
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.抗精神病药物治疗精神分裂症的有效性：一项前瞻性观察性研究（IC-SOHO）比较奥氮平、喹硫平、利培酮和氟哌啶醇的6个月中期分析。
J Clin Psychiatry. 2004 Mar;65(3):312-21.
4
The new antipsychotic compounds: is a clinical choice algorithm possible?新型抗精神病药物：是否有可能建立一种临床选择算法？
West J Med. 1998 Jul;169(1):43-4.
5
Two new atypical antipsychotics: advantages and disadvantages.两种新型非典型抗精神病药物：优缺点
S D J Med. 1998 Aug;51(8):285-6.
6
[Current pharmacotherapy of schizophrenia].[精神分裂症的当前药物治疗]
Orv Hetil. 2004 Jan 18;145(3):105-9.
7
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.抗精神病药物对慢性精神分裂症患者的疗效。
N Engl J Med. 2005 Sep 22;353(12):1209-23. doi: 10.1056/NEJMoa051688. Epub 2005 Sep 19.
8
Focus on the metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there differences?关注奥氮平、喹硫平和利培酮长期治疗的代谢后果：有差异吗？
Int J Neuropsychopharmacol. 2005 Jun;8(2):153-6. doi: 10.1017/S1461145705005183. Epub 2005 Mar 21.
9
The value of atypical antipsychotics in the treatment of schizophrenia.非典型抗精神病药物在精神分裂症治疗中的价值。
Manag Care. 2002 Jul;11(7 Suppl):8-12; discussion 12-3.
10
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.奥氮平、喹硫平和利培酮治疗早期精神病的疗效与耐受性：一项随机双盲52周比较研究。
Am J Psychiatry. 2007 Jul;164(7):1050-60. doi: 10.1176/ajp.2007.164.7.1050.
引用本文的文献
1
Disconnected and Hyperactive: A Replication of Sensorimotor Cortex Abnormalities in Patients With Schizophrenia During Proactive Response Inhibition.断开连接且过度活跃：精神分裂症患者在主动反应抑制过程中感觉运动皮层异常的复制。
Schizophr Bull. 2019 Apr 25;45(3):552-561. doi: 10.1093/schbul/sby086.
2
Adverse effects of clozapine in older patients: epidemiology, prevention and management.氯氮平在老年患者中的不良反应：流行病学、预防和管理。
Drugs Aging. 2014 Jan;31(1):11-20. doi: 10.1007/s40266-013-0144-2.
3
Atypical antipsychotics and diabetic ketoacidosis: a review.非典型抗精神病药物与糖尿病酮症酸中毒：综述。
Psychopharmacology (Berl). 2013 Mar;226(1):1-12. doi: 10.1007/s00213-013-2982-3. Epub 2013 Jan 24.
4
Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia.超越多巴胺受体：治疗精神分裂症的新型治疗靶点。
Dialogues Clin Neurosci. 2010;12(3):359-82. doi: 10.31887/DCNS.2010.12.3/jcoyle.
本文引用的文献
1
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.封面文章：抗精神病药物诱导的体重增加由组胺H1受体介导的下丘脑AMP激酶激活所致。
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3456-9. doi: 10.1073/pnas.0611417104. Epub 2007 Feb 20.
2
The metabolic syndrome: concepts and controversy.代谢综合征：概念与争议
Mayo Clin Proc. 2006 Dec;81(12):1615-20. doi: 10.4065/81.12.1615.
3
A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents.一项关于二甲双胍治疗儿童和青少年非典型抗精神病药物治疗引发体重增加的随机、双盲、安慰剂对照试验。
Am J Psychiatry. 2006 Dec;163(12):2072-9. doi: 10.1176/ajp.2006.163.12.2072.
4
Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).第二代与第一代抗精神病药物对精神分裂症患者生活质量影响的随机对照试验：精神分裂症最新抗精神病药物的成本效用研究（CUtLASS 1）
Arch Gen Psychiatry. 2006 Oct;63(10):1079-87. doi: 10.1001/archpsyc.63.10.1079.
5
AMP-activated protein kinase as a drug target.AMP激活的蛋白激酶作为一种药物靶点。
Annu Rev Pharmacol Toxicol. 2007;47:185-210. doi: 10.1146/annurev.pharmtox.47.120505.105304.
6
Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era.非典型抗精神病药物时代前后精神分裂症患者糖尿病患病率及非相关普通内科疾病的差异趋势。
Schizophr Res. 2006 Sep;86(1-3):99-109. doi: 10.1016/j.schres.2006.04.014. Epub 2006 Jun 6.
7
The hypothalamic H1 receptor: a novel therapeutic target for disrupting diurnal feeding rhythm and obesity.下丘脑H1受体：破坏昼夜进食节律和肥胖的新型治疗靶点。
Trends Pharmacol Sci. 2006 May;27(5):279-84. doi: 10.1016/j.tips.2006.03.008. Epub 2006 Apr 11.
8
Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic.在使用安慰剂或活性抗精神病药物对精神分裂症进行急性治疗期间，体重增加作为治疗改善的预后指标。
J Psychopharmacol. 2005 Nov;19(6 Suppl):110-7. doi: 10.1177/0269881105058978.
9
The metabolic syndrome and schizophrenia: a review.
Int Rev Psychiatry. 2005 Jun;17(3):173-80. doi: 10.1080/09540260500071798.
10
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.抗精神病药物对慢性精神分裂症患者的疗效。
N Engl J Med. 2005 Sep 22;353(12):1209-23. doi: 10.1056/NEJMoa051688. Epub 2005 Sep 19.
Zotero 插件